Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician

Patients with prosthetic heart valves require chronic oral anticoagulation. In this clinical scenario, physicians must be mindful of the thromboembolic and bleeding risks related to chronic anticoagulant therapy. Currently, only vitamin K antagonists are approved for this indication. This paper revi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thrombosis and thrombolysis 2011-05, Vol.31 (4), p.514-522
Main Authors: Leiria, Tiago L. L., Lopes, Renato D., Williams, Judson B., Katz, Jason N., Kalil, Renato A. K., Alexander, John H.
Format: Article
Language:English
Subjects:
Administration, Oral
Anticoagulants - administration & dosage
Anticoagulants - adverse effects
Cardiology
Fibrinolytic Agents - administration & dosage
Fibrinolytic Agents - adverse effects
Heart Valve Prosthesis
Hematology
Humans
Medicine
Medicine & Public Health
Practice Guidelines as Topic
Thromboembolism - prevention & control
Vitamin K - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with prosthetic heart valves require chronic oral anticoagulation. In this clinical scenario, physicians must be mindful of the thromboembolic and bleeding risks related to chronic anticoagulant therapy. Currently, only vitamin K antagonists are approved for this indication. This paper reviews the main heart valve guidelines focusing on the use of oral anticoagulation in these patients.
ISSN:0929-5305
1573-742X
DOI:10.1007/s11239-011-0574-9